These biological processes might contribute to explaining why GFAP is the strongest risk marker for clinical diagnosis of dementia among ESTHER participants with a high prevalence of mixed pathology and why GFAP plays a key role for all-cause dementia but not for the risk of depression in the absence of dementia. This evidence concerns the gene GFAP and depressive symptom measurement.